Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced ...
Pharmaceutical Technology on MSN
JPM26: BioNTech gears up for multiproduct oncology status by 2030
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...
AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities ...
Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, ...
Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Despite alarming federal budget cuts that stand to potentially harm the ...
We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks under ...
We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against the other oversold biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback